# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BridgeBio Pharma (NASDAQ:BBIO) with a Buy and maintains $43 pr...
- Acoramidis treatment resulted in increased serum transthyretin (TTR) levels by Day 28 that were sustained and were correlated...
Cantor Fitzgerald analyst Josh Schimmer reiterates BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and maintains $70 price ...
UBS analyst Eliana Merle maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and lowers the price target from $51 to $47.
The 2024 International Symposium on Amyloidosis (ISA) is taking place in Rochester, Minnesota on May 26 - 30, 2024.
HC Wainwright & Co. analyst Raghuram Selvaraju maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and lowers the price ...
Evercore ISI Group analyst Cory Kasimov initiates coverage on BridgeBio Pharma (NASDAQ:BBIO) with a Outperform rating and an...
This capital raise provides BBOT with runway to achieve significant clinical inflection points over the next 18-24 months as it...